Novartis AG (NVS) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 75.0% | 31.2% | 25.6% |
| 2024 | 75.2% | 28.1% | 23.1% |
| 2023 | 73.3% | 20.9% | 31.8% |
| 2022 | 73.4% | 18.3% | 16.0% |
| 2021 | 73.3% | 22.9% | 54.6% |
Download Data
Export NVS earnings history in CSV or JSON format
Free sign-in required to download data
Novartis AG (NVS) Earnings Overview
As of March 2, 2026, Novartis AG (NVS) reported trailing twelve-month net income of $13.98B, reflecting +0.2% year-over-year growth. The company earned $7.25 per diluted share over the past four quarters, with a net profit margin of 0.3%.
Looking at the long-term picture, NVS's 5-year EPS compound annual growth rate (CAGR) stands at +15.4%, indicating exceptional earnings growth. The company achieved its highest annual net income of $24.02B in fiscal 2021.
Novartis AG maintains positive profitability with a gross margin of 0.8%, operating margin of 0.3%, and net margin of 0.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including OGN ($187M net income, 0.0% margin), SRXH (N/A net income, -0.1% margin), NVS has outperformed on profitability metrics. Compare NVS vs OGN →
Peer Comparison
Earnings metrics vs industry competitors
| Company | TTM Net Income | TTM EPS | Net Margin | ROE | YoY Growth | Compare |
|---|---|---|---|---|---|---|
NVSCurrent | $14.0B | $7.25 | 0.3% | 0.3% | +0.2% | — |
OGN | $187M | $0.72 | 0.0% | 0.3% | -0.8% | |
SRXH | - | - | -0.1% | - | +0.7% |
Historical Data
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $14.06B | +17.7% | $17.07B | $7.19 | 25.6% | 31.2% |
| 2024 | $11.94B | -19.6% | $14.54B | $5.87 | 23.1% | 28.1% |
| 2023 | $14.85B | +113.5% | $9.77B | $7.10 | 31.8% | 20.9% |
| 2022 | $6.96B | -71.0% | $7.95B | $3.17 | 16.0% | 18.3% |
| 2021 | $24.02B | +197.6% | $10.06B | $10.63 | 54.6% | 22.9% |
| 2020 | $8.07B | -31.2% | $10.15B | $3.52 | 16.2% | 20.3% |
| 2019 | $11.73B | -7.0% | $9.09B | $3.08 | 24.1% | 18.7% |
| 2018 | $12.61B | +63.7% | $8.40B | $5.38 | 27.4% | 18.2% |
| 2017 | $7.70B | +14.8% | $8.70B | $3.25 | 17.7% | 20.0% |
| 2016 | $6.71B | -62.3% | $8.27B | $2.80 | 13.6% | 16.7% |
See NVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NVS vs AGIO
See how NVS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is NVS growing earnings?
NVS EPS of $7.25 reflects slowing growth at +0.2%, below the 5-year CAGR of +15.4%. TTM net income is $14.0B. Expansion rate has moderated.
What are NVS's profit margins?
Novartis AG net margin is +0.3%, with operating margin at +0.3%. Below-average margins reflect competitive or cost pressures.
How consistent are NVS's earnings?
NVS earnings data spans 1998-2025. The current earnings trend is +0.2% YoY. Historical data enables comparison across business cycles.